Oncology Institute (TOI) Competitors

$5.19 +0.06 (+1.09%)

Closing price 08/3/2026

Extended Trading

$5.19 0.00 (0.00%)

As of 08/3/2026 07:55 PM Eastern

TOI vs. AVAH, MD, GRDN, ASTH, and AGL

Should you buy Oncology Institute stock or one of its competitors? Oncology Institute's main competitors and comparable companies include Aveanna Healthcare (AVAH), Pediatrix Medical Group (MD), Guardian Pharmacy Services (GRDN), Astrana Health (ASTH), and Agilon Health (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Oncology Institute compare to Aveanna Healthcare?

Oncology Institute (NASDAQ:TOI) and Aveanna Healthcare (NASDAQ:AVAH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Oncology Institute has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Aveanna Healthcare has a net margin of 10.56% compared to Oncology Institute's net margin of -7.42%. Aveanna Healthcare's return on equity of 99.71% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Aveanna Healthcare	10.56%	99.71%	7.57%

In the previous week, Aveanna Healthcare had 21 more articles in the media than Oncology Institute. MarketBeat recorded 22 mentions for Aveanna Healthcare and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.66 beat Aveanna Healthcare's score of 0.60 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Aveanna Healthcare	Positive

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aveanna Healthcare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A
Aveanna Healthcare	$2.43B	1.10	$225.03M	$1.18	10.44

Oncology Institute currently has a consensus price target of $8.50, suggesting a potential upside of 63.90%. Aveanna Healthcare has a consensus price target of $11.78, suggesting a potential downside of 4.40%. Given Oncology Institute's higher probable upside, research analysts plainly believe Oncology Institute is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Aveanna Healthcare beats Oncology Institute on 15 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Pediatrix Medical Group?

Oncology Institute (NASDAQ:TOI) and Pediatrix Medical Group (NYSE:MD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Pediatrix Medical Group has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A
Pediatrix Medical Group	$1.91B	1.13	$165.39M	$2.09	12.72

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 97.7% of Pediatrix Medical Group shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by insiders. Comparatively, 1.8% of Pediatrix Medical Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncology Institute has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Pediatrix Medical Group has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

In the previous week, Pediatrix Medical Group had 6 more articles in the media than Oncology Institute. MarketBeat recorded 7 mentions for Pediatrix Medical Group and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.66 beat Pediatrix Medical Group's score of 0.65 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Pediatrix Medical Group	Positive

Oncology Institute presently has a consensus target price of $8.50, suggesting a potential upside of 63.90%. Pediatrix Medical Group has a consensus target price of $24.83, suggesting a potential downside of 6.58%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Pediatrix Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pediatrix Medical Group	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pediatrix Medical Group has a net margin of 8.96% compared to Oncology Institute's net margin of -7.42%. Pediatrix Medical Group's return on equity of 20.05% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Pediatrix Medical Group	8.96%	20.05%	8.15%

Summary

Pediatrix Medical Group beats Oncology Institute on 11 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Guardian Pharmacy Services?

Guardian Pharmacy Services (NYSE:GRDN) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

In the previous week, Guardian Pharmacy Services had 8 more articles in the media than Oncology Institute. MarketBeat recorded 9 mentions for Guardian Pharmacy Services and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.66 beat Guardian Pharmacy Services' score of 0.72 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
Guardian Pharmacy Services	Positive
Oncology Institute	Very Positive

Guardian Pharmacy Services has a net margin of 4.50% compared to Oncology Institute's net margin of -7.42%. Guardian Pharmacy Services' return on equity of 29.97% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardian Pharmacy Services	4.50%	29.97%	16.18%
Oncology Institute	-7.42%	N/A	-24.68%

Guardian Pharmacy Services has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardian Pharmacy Services	$1.45B	1.32	$49.22M	$1.03	37.27
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A

Guardian Pharmacy Services currently has a consensus price target of $43.83, indicating a potential upside of 14.20%. Oncology Institute has a consensus price target of $8.50, indicating a potential upside of 63.90%. Given Oncology Institute's higher probable upside, analysts clearly believe Oncology Institute is more favorable than Guardian Pharmacy Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardian Pharmacy Services	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Guardian Pharmacy Services has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

36.9% of Oncology Institute shares are held by institutional investors. 33.0% of Guardian Pharmacy Services shares are held by company insiders. Comparatively, 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Guardian Pharmacy Services beats Oncology Institute on 12 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Astrana Health?

Astrana Health (NASDAQ:ASTH) and Oncology Institute (NASDAQ:TOI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Astrana Health has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.71	$22.49M	$0.82	49.77
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A

In the previous week, Astrana Health had 9 more articles in the media than Oncology Institute. MarketBeat recorded 10 mentions for Astrana Health and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.66 beat Astrana Health's score of 0.42 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
Astrana Health	Neutral
Oncology Institute	Very Positive

Astrana Health has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Astrana Health has a net margin of 1.05% compared to Oncology Institute's net margin of -7.42%. Astrana Health's return on equity of 10.30% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Oncology Institute	-7.42%	N/A	-24.68%

52.8% of Astrana Health shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 20.3% of Astrana Health shares are held by insiders. Comparatively, 4.4% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Astrana Health currently has a consensus target price of $49.43, suggesting a potential upside of 21.12%. Oncology Institute has a consensus target price of $8.50, suggesting a potential upside of 63.90%. Given Oncology Institute's higher possible upside, analysts plainly believe Oncology Institute is more favorable than Astrana Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Astrana Health beats Oncology Institute on 13 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Agilon Health?

Agilon Health (NYSE:AGL) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Agilon Health presently has a consensus price target of $86.18, indicating a potential downside of 10.80%. Oncology Institute has a consensus price target of $8.50, indicating a potential upside of 63.90%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Agilon Health had 3 more articles in the media than Oncology Institute. MarketBeat recorded 4 mentions for Agilon Health and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.66 beat Agilon Health's score of 0.14 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
Agilon Health	Neutral
Oncology Institute	Very Positive

Agilon Health has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

36.9% of Oncology Institute shares are held by institutional investors. 2.5% of Agilon Health shares are held by company insiders. Comparatively, 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Agilon Health has a net margin of -3.92% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-3.92%	-119.38%	-16.85%
Oncology Institute	-7.42%	N/A	-24.68%

Oncology Institute has lower revenue, but higher earnings than Agilon Health. Oncology Institute is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.93B	0.27	-$391.35M	-$14.27	N/A
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A

Summary

Oncology Institute beats Agilon Health on 9 of the 15 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOI vs. The Competition

Export

Metric	Oncology Institute	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$512.58M	$9.88B	$6.98B	$13.04B
Dividend Yield	N/A	2.55%	2.58%	10.72%
P/E Ratio	-14.02	35.18	269.86	25.30
Price / Sales	0.94	4.80	601.81	101.06
Price / Cash	N/A	124.00	70.53	50.75
Price / Book	-32.41	5.35	13.08	6.33
Net Income	-$60.61M	$309.96M	$3.45B	$347.70M
7 Day Performance	N/A	0.21%	1.12%	1.07%
1 Month Performance	-17.42%	0.60%	1.79%	1.03%
1 Year Performance	41.31%	20.36%	67.69%	20.77%

Oncology Institute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOI Oncology Institute	3.7432 of 5 stars	$5.19 +1.1%	$8.50 +63.9%	+26.5%	$512.58M	$545.76M	N/A	660	Positive News Gap Down
AVAH Aveanna Healthcare	4.1765 of 5 stars	$9.36 -2.6%	$10.78 +15.1%	+57.9%	$2.04B	$2.43B	7.93	35,500	Trending News Earnings Report Analyst Forecast Gap Up
MD Pediatrix Medical Group	2.2162 of 5 stars	$24.71 -5.9%	$23.33 -5.6%	+70.4%	$2.03B	$1.93B	12.00	4,315	Gap Down
GRDN Guardian Pharmacy Services	3.2772 of 5 stars	$40.63 -0.5%	$42.83 +5.4%	+61.9%	$2.02B	$1.45B	48.95	3,600
ASTH Astrana Health	3.6884 of 5 stars	$35.70 -0.6%	$47.86 +34.1%	+27.5%	$1.99B	$3.18B	58.52	3,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncology Institute (TOI) Competitors

TOI vs. AVAH, MD, GRDN, ASTH, and AGL

How does Oncology Institute compare to Aveanna Healthcare?

Summary

How does Oncology Institute compare to Pediatrix Medical Group?

Summary

How does Oncology Institute compare to Guardian Pharmacy Services?

Summary

How does Oncology Institute compare to Astrana Health?

Summary

How does Oncology Institute compare to Agilon Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncology Institute (TOI) Competitors

TOI vs. AVAH, MD, GRDN, ASTH, and AGL

How does Oncology Institute compare to Aveanna Healthcare?

Which has more risk and volatility, TOI or AVAH?

Is TOI or AVAH more profitable?

Does the media favor TOI or AVAH?

Do institutionals and insiders hold more shares of TOI or AVAH?

Which has preferable earnings and valuation, TOI or AVAH?

Do analysts prefer TOI or AVAH?

Summary

How does Oncology Institute compare to Pediatrix Medical Group?

Which has stronger valuation and earnings, TOI or MD?

Do insiders and institutionals hold more shares of TOI or MD?

Which has more risk & volatility, TOI or MD?

Does the media favor TOI or MD?

Do analysts prefer TOI or MD?

Is TOI or MD more profitable?

Summary

How does Oncology Institute compare to Guardian Pharmacy Services?

Does the media favor GRDN or TOI?

Is GRDN or TOI more profitable?

Which has stronger earnings & valuation, GRDN or TOI?

Do analysts recommend GRDN or TOI?

Which has more risk & volatility, GRDN or TOI?

Do insiders and institutionals believe in GRDN or TOI?

Summary

How does Oncology Institute compare to Astrana Health?

Which has stronger valuation and earnings, ASTH or TOI?

Does the media prefer ASTH or TOI?

Which has more volatility & risk, ASTH or TOI?

Is ASTH or TOI more profitable?

Do institutionals and insiders hold more shares of ASTH or TOI?

Do analysts rate ASTH or TOI?

Summary

How does Oncology Institute compare to Agilon Health?

Do analysts prefer AGL or TOI?

Does the media refer more to AGL or TOI?

Which has more volatility and risk, AGL or TOI?

Do institutionals and insiders believe in AGL or TOI?

Is AGL or TOI more profitable?

Which has higher earnings and valuation, AGL or TOI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools